February 10, 2026
Oyedele et al. (2026) “A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial” Vaccine.
DOI: 10.1016/j.vaccine.2026.128304